Kornimate/medical-research-clean huggingface dataset:
unravelling the role of kctd protein family in the clinical management of childhood acute lymphoblastic leukemias

Conditions: Childhood Acute Lymphoblastic Leukemia

Summary: a transcriptomic analysis of bone marrow from b-all patients was performed by our research group for identifying novel protein/factor with a putative role of disease biomarker. along with some already known b-all biomarkers, our analysis highlighted deregulation of some members of an emerging protein class denoted as kctd (potassium channeltetramerization domain-containing proteins). starting from our preliminary observations, and considering that kctds havenever been studied in all, we decided to study these proteins in b- and t-all affected pediatric patients, enrolled by our research group in collaboration with aorn santobono-pausilipon pediatric oncological hospital.indeed, the present research program aims at opening a new scenario for the study of kctd proteins in childhood leukemias. the final goal of the project will be to evaluate the translational relevance of selected deregulated kctds as novel biomarkers useful for b-all and t-all diagnostics, and patient management.


Eligibility criteria:
inclusion criteria: * patients aged 1-18 years of both sexes diagnosed with b- all and t-all; * patients who will have signed the informed consent exclusion criteria: * patients who refuse to participate in the study; * patients who do not fall within the age range mentioned above
validation of actigraph measured sleep during acute diverticulitis

Conditions: Acute Diverticulitis

Summary: the purpose of this study is to investigate the accuracy of actigraph measured sleep compared to the golden standard (polysomnography) during acute uncomplicated diverticulitis. our hypothesis is the actigraph is accurate for sleep-monitoring for this group of patients

the actigraph has been proven to measured sleep data with an accuracy about 80% (compared with polysomnography) in patients who have undergone surgery. but this accuracy has not been validated in relation to none surgical inflammatory diseases. this study will investigate the accuracy of actigraph measured sleep in diverticulitis patients. following methods will be applied device: wrist-actigraph - octagonal basic motionlogger, ambulatory monitoring inc, new york, usa other: sleep-diary device: polysomnograph - embla titanium (natus medical incorporated, usa)

Eligibility criteria:
inclusion criteria: * ct-verified diverticulitis patients managed by antibiotic treatment at herlev hospital * pain and fever occurred less than 72 hours prior to the admission * asa (american society of anesthesiologists) score i to iii exclusion criteria: * surgical intervention needed * complicated diverticulitis * complications in relation to diverticulitis * pain and fever occurred more than 72 hours prior to the admission * in anticoagulant treatment and heart rate control treatment * known autoimmune disease * known medically treated sleep-disorder (insomnia, restless legs etc.) and sleep apnea * shift-work or jetlag * daily use of opioid, psychopharmaca, opioids or anxiolytics (including hypnotics) * known psychiatry conditions in treatment with psychopharmaca * daily alcohol intake of more than 5 units or drug abuse * missing written consent * diabetes mellitus * predicted bad compliance * pregnant or breast-feeding * urine or fecal incontinence * severe kidney disease * current cancer
improving asthma treatment using inhaler technology

Conditions: Asthma

Summary: this study will use inhaler technology to observe and feedback overall patterns of medication use. we will look at whether this improves preventer inhaler use and reduces reliever inhaler overuse. we will also assess whether inhaler technology is patient-friendly and cost effective, whether it helps with treatment decisions in asthma and whether it can help us to predict and prevent asthma attacks.

the smarttouch™ range of electronic casings will record the use of metered dose inhalers (mdi) by participants in the study. the actuation data can be remotely viewed and analyzed by the investigators. the hypothesis is that employing such technology to measure medication patterns and to help provide patient feedback improves inhaler adherence and potentially clinical outcomes (asthma control and exacerbations) in asthma patients with recent asthma attacks in a practical, real-world setting. we will assess whether electronic inhaler data capture can identify patients requiring more frequent reviews or treatment change and enable proactive self- management. using qualitative methods, we will explore participants' attitudes to their asthma management, whether the use of inhaler technology has had an impact on this and whether they found its use acceptable.

Eligibility criteria:
inclusion criteria: * use of systemic corticosteroids for worsening asthma (or an increase from baseline dose in patients on long-term oral corticosteroids) in the prior 12 months \[i.e. at least one asthma exacerbation requiring additional systemic corticosteroid in the prior 12 months\] patient reported. * doctor's diagnosis of asthma for at least 12 months * on bts step 2-5 treatment via mdi \[monitoring devices to be utilised in the study are compatible with mdi inhalers\] * use of own internet-enabled and compatible mobile phone exclusion criteria: * diagnosis of copd or onset of symptoms after the age of 40 in patients with ≥10 pack year history of smoking * other clinically significant coexisting respiratory disease e.g. fibrosis, bronchiectasis * patients on maintenance and reliever therapy ('smart' or 'fostair® mart')

Keywords: inhaler
health questionnaire study

Conditions: Anxiety Disorder (Panic Disorder or GAD); Depression - Major Depressive Disorder

Summary: we want to explore if emphasizing certain instructions (i.e. "bothered by") will affect the way participants respond to a questionnaire.


Eligibility criteria:
inclusion criteria: * 18 or older * u.s. resident * self-report being treated for or receiving a diagnosis generalized anxiety disorder or major depressive disorder by a licensed provider (e.g., md, do, lpcc, lcsw, lmft) in the past 12 months exclusion criteria: -
rep1 gene replacement therapy for choroideremia

Conditions: Choroideremia

Summary: the assessment of the efficacy (with respect to preservation of visual function and retinal structure) and safety of a single subretinal injection of aav2.rep1 in participants with a confirmed diagnosis of choroideremia, as evaluated by various functional and anatomical outcomes measured over a number of time points up to 24 months post-treatment.


Eligibility criteria:
inclusion criteria: 1. candidate is willing and able to give informed consent for participation in the study. 2. male aged 18 years or above. 3. genetic or molecular confirmed diagnosis of choroideremia (rep1 protein deficiency). 4. active disease visible clinically within the macula region. 5. best corrected visual acuity better than or equal to 6/60 (20/200; decimal 0.1; logmar 1.0) in the study eye. exclusion criteria: 1. any female, or a male aged below 18 years. 2. an additional cause for sight loss (e.g. amblyopia) in the eye to be treated. 3. any other significant ocular and non-ocular disease or disorder which, in the opinion of the investigator, may put the participants at risk because of participation in the study. 4. inability to take systemic prednisolone for a period of 45 days. 5. unwillingness to use barrier contraception methods for a period of three months following gene therapy surgery. 6. participation in another research study involving an investigational product in the preceding 12 weeks.
thromboelastography as a tool for possible clopidogrel resistance in the patients treated with primary pci for stemi

Conditions: Myocardial Infarction; Cardiovascular Disease

Summary: determine usefulness of thromboelastography (teg) as a valuable tool in ex-vivo assessing platelet response to aspirin and clopidogrel (dual) treatment and on-treatment platelet reactivity during acute st segment elevation myocardial infarction (stemi) in an acute phase during primary pci (ppci) and also during recovery been on maintenance medical therapy and to determine the correlation between platelet response to clopidogrel treatment and the outcome of patients.

dual anti-aggregant therapy is recommended standard of therapy applicable to all patient groups undergoing ppci. the aspirin-clopidogrel regiment is signed to every patient without assessing therapeutic effect. in face of growing evidence of platelet resistance to the standardized therapy there is a demand for reliable diagnostic tool for rapid and accurate assessment of platelet reactivity. teg is an established technique to assess the quality of clot formation' used mainly in surgery and obstetrics to determine possible bleeding diathesis. recently it became to be used in cardiology, where it can be a valuable tool to assess a response to antiplatelet therapy and its association with the outcome. however, there is a few data about use of teg in stemi patients undergoing pci. our study is designed to assess by teg the platelet's response to clopidogrel treatment during acute stemi in patients undergoing primary pci and the correlation of this response with the long term outcome.

Eligibility criteria:
inclusion criteria: * \>18 years old stemi patients admitted to iccu and in whom the primary pci is elected as treatment strategy would be enrolled exclusion criteria: * patient received thrombolytic therapy, chronic renal failure (gfr\<40 ml/min), any known hematological dyscrasia
zinc supplementation and behçet's syndrome

Conditions: Behcet Syndrome

Summary: to study the effects of zinc gluconate supplementation on patients with behçet's syndrome, 50 patients will be randomly allocated to two groups: placebo group or zinc group (one tablet of 30 mg/day elemental zinc) for 12 weeks. all participants will be asked not to alter their diet, medication, and physical activity during the study. at the first and the end of the intervention, genes and proteins expression, the serum level of inflammatory factors, quality of life, disease activity, anthropometric measures, physical activity and serum level of zinc will be assessed and compared between groups.


Eligibility criteria:
inclusion criteria: * age range 20 to 50 years (premenopausal woman) * diagnosis of behcet's disease by a rheumatologist according to ibcd (the international criteria for behcet's disease) * patients who want to participate in the study exclusion criteria: * pregnancy and lactation * history of diabetes and other chronic diseases * smoking and alcohol consumption over the past year * history of other autoimmune diseases * consumption of nutritional and antioxidant supplements over two months prior to the study
diaphragmatic echography after thoracic surgery

Conditions: Surgery, Thoracic; Respiratory Diaphragm; Complication, Postoperative

Summary: the investigator evaluated diaphragmatic function in patients undergoing thoracic surgery. diaphragmatic displacement was evaluated before surgery, 2 and 24 hours after surgery. also, preoperative spirometry and postoperative spirometry were collected (24 hours after surgery).


Eligibility criteria:
inclusion criteria: * elective surgery for lung cancer * age \> 18 * asa 2-3 exclusion criteria: * bmi \> 35 * contraindications for epidural catheter positioning * history of neurodegenerative pathology * previous thoracic surgery * need for mechanical ventilation after surgery
zero ischemia robot-assisted mwa assisted suture-less tumor enucleation of rcc with t1 stage

Conditions: Kidney Neoplasms

Summary: zero ischemia laparoscopic radio frequency ablation assisted tumor enucleation has been proved to enable tumor excision with relatively better renal function preservation comparing with conventional laparoscopic partial nephrectomy for t1a renal cell carcinoma (rcc) in a randomized clinical trial in single center. the investigators want to explore this technique to robotic surgery and add suture-less technique to t1 rcc patients in randomized clinical trial.

zero ischemia laparoscopic radio frequency ablation assisted tumor enucleation has been proved to enable tumor excision with relatively better renal function preservation comparing with conventional laparoscopic partial nephrectomy for t1a renal cell carcinoma (rcc) in a randomized clinical trial in single center. the investigators want to explore this technique to robotic surgery and add suture-less technique to t1 rcc patients in randomized clinical trial. this project is based on the previous research and aims to develop an approach of the combination of intraoperative real time contrast-enhanced ultrasonography technology, sutureless technology and the zero ischemia robot-assisted tumor enucleation of the kidney. by using the real time contrast-enhanced ultrasonography technology, the current shortcomings of the zero ischemia laparoscopic radio frequency ablation assisted tumor enucleation were overcome. the degree of elimination was monitored during surgery to avoid excessive bleeding caused by insufficient ablation during the surgery. beside, the difficulty of zero ischemia laparoscopic radio frequency ablation is reduced, and doctors can quickly grasp the learning curve of this technology.

Eligibility criteria:
inclusion criteria: 1. patients with sporadic, unilateral, newly diagnosed t1 presumed renal cell carcinoma 2. patients scheduled for robot-assisted laparoscopic nephron sparing surgery 3. patients with normal contralateral renal function (differential renal function of \>40% as determined by radionuclide scintigraphy) 4. patients agreeable to participate in this long-term follow-up study exclusion criteria: 1. patients' age \>80 years 2. patients with other renal diseases (including kidney stone, glomerular nephritis, etc.)which might affect the renal function of the operative kidney 3. patients not able to tolerate the robot-assisted laparoscopic procedure 4. patients with previous renal surgery or history of any inflammatory conditions of the operative kidney 5. patients with the renal tumor involving urinary collecting system or distance from the tumor edge to the collecting system ≤ 4 mm

Keywords: microwave ablation nephronsparing surgery zero ischemia suture less
ulipristal acetate 10 mg and asisted reproduction

Conditions: Intramural Fibroids; Uterine Fibroids

Summary: demonstrate an 15% increase in the rate of clinical pregnancy in women with inoperable intramural fibroids not distorting the uterine cavity within a program ovd, after administration of upa in a dose of 10 mg orally daily for 12 weeks


Eligibility criteria:
inclusion criteria: patients\> 18 and \ 2 cm and \<5 cm that do not distort the cavity, type 3 and 4 of the figo classification (figure 1). miomas inoperable for medical judgment or patient desire, you want to avoid the post-surgical time waiting 6 months / 1 year before you can submit to tra patients who have undergone previous myomectomy who prefer to avoid having surgery exclusion criteria: history of endometrial changes in patients (hyperplasia) presence of other endometrial pathologies: polyps, scars of previous cesarean complicated adenomyosis foci, suspected adhesions simultaneous participation in another clinical study
effect of atomoxetine on adhd-related insomnia in children and adolescents

Conditions: Attention-Deficit/Hyperactivity Disorder (ADHD); Insomnia

Summary: children and adolescents with attention-deficit/hyperactivity disorder (adhd) very commonly experience difficulty in initiating and maintaining sleep. studies have shown that daytime sleepiness resulting from insufficient sleep can affect attention and learning. therefore, treating insomnia in children with adhd may not only improve sleep, but it could potentially improve adhd symptoms as well. the main purpose of this study is to examine the effects of atomoxetine on adhd-related insomnia. atomoxetine (strattera®) is a non-stimulant drug used to treat adhd symptoms in both children and adults, and there is evidence that it may also have a positive effect on sleep in children with adhd. during the study, participants will receive either atomoxetine or placebo for a period of four weeks. we expect that the effects of atomoxetine on sleep will differ from those of placebo, with atomoxetine having a greater effect on improving sleep difficulties.


Eligibility criteria:
inclusion criteria: * boy or girl aged 6-17 years, inclusive, and english-speaking * meet the dsm-iv criteria for attention-deficit/hyperactivity disorder * have sleep initiation defined by: 1. difficulty initiating or maintaining sleep that is viewed as a problem by the child or caregiver 2. sleep onset delay that is not exclusively related to direct or rebound effects of psychostimulant treatment * have a parent or legal guardian willing to participate in the study exclusion criteria: * have any other primary sleep disorder(s) (e.g. obstructive sleep apnea or periodic limb movement disorder) * have a history of significant chronic medical (e.g. diabetes, severe asthma) or psychiatric (e.g. depression) illness * have a history of chronic use of sedating (e.g. antihistamines) or alertness enhancing (e.g. caffeine) medications * have a history of failure to respond to an adequate (defined as appropriate dose and adequate duration of therapy) previous trial with atomoxetine
pulmonary nodule detection: comparison of an ultra low dose vs standard scan.

Conditions: Lung Cancer; Smoking; Radiation Exposure

Summary: lung cancer screening programs are still discussed in europe today, and one of the concern is radiation due to iterative ct. the aim of this monocentric, prospective, non randomized study is to compare an ultra low dose chest ct (approaching a two views x ray) versus a standard low dose chest ct for ≥4mm lung nodules detection, and secondary for lung nodule characterization and smoking associated findings (emphysema, bronchial abnormalities and coronary calcifications).

an additional ultra low dose ct, approaching 0.2msv, will be performed in consenting patients referred for non enhanced chest ct in our revolution ct scanner (ge healthcare®).the dose delivered with the two acquisitions is still lower than the french diagnostic reference level. standard ct is interpreted and a report is sent to the referent physician as usual. then the two acquisitions are read over time by two independent radiologists, blinded over judgment criterias. in case of discordance, an other radiologist will arbitrate. we hope to validate our ultra low dose chest ct protocol, which is more than 10 times less radiating than a standard low dose ct, as a sensitive tool to detect lung nodules.

Eligibility criteria:
inclusion criteria : 1. patients referred for non enhanced chest ct for following indications : * lung nodule search or control * nodular abnormality on chest x ray * statement of copd or emphysema * asbestos exposure * nodule localization before radio frequency ablation * assessment of disease extent of an extra thoracic cancer (in case of iodinated intravenous contrast agent contraindication) * statement before extrathoracic transplantation (in case of iodinated intravenous contrast agent contraindication) 2. affiliated with the french social security 3. who signed consent exclusion criteria : 1. inability to lie down and still during the examination 2. inability to hold breath more than 5 seconds 3. pneumonia in the last 3 months 4. body mass index more than 35kg/m² 5. exclusion period of another interventionnal study 6. referred for articles l1121-5 to l1121-8 of french public health code 7. pregnant or breastfeeding women

Keywords: ultra low dose chest ct lung cancer screening
evaluation of myocardial ischemia using standard single photon emission computed tomography (spect) with regadenoson and simultaneous cardiac echocardiography

Conditions: Myocardial Ischemia

Summary: this study is for people who have a spect scan (nuclear imaging of the blood flow to the heart muscle) ordered by their medical doctors. as part of the spect scan, they will have been given a drug called regadenoson to widen and expand the blood vessels bringing blood to the heart muscle. the spect pictures of the heart are taken about an hour after the regadenoson is put into an arm vein through an iv. in this study, additional echo pictures will be taken and compared to the spect pictures. the aim of the study is to see if the echo pictures work as well as spect to measure the blood flow to the heart muscle.

this is a single center, prospective, non-randomized, comparative, same-setting study of lexiscan mpi spect versus state-of-the-art echocardiography. lexiscan spect mpi will be performed per routine clinical protocol with lexiscan administered as per package insert (0.4 mg in 5 ml iv push over 10 seconds followed by a 5 ml saline flush). simultaneous echo/doppler will be obtained immediately before (baseline), during and immediately post (peak vasodilation) using conventional techniques.

Eligibility criteria:
inclusion criteria: * patients referred to a university of arizona/sarver heart center/university medical center stress imaging laboratory and scheduled to receive a regadenoson spect nuclear scan. exclusion criteria: * patients unable or unwilling to undergo the clinically necessary stress test or to provide informed consent.

Keywords: echocardiography, 2d speckle tracking lexiscan regadenoson myocardial ischemia myocardial perfusion imaging cost and cost analysis cardiac-gated spect imaging echocardiography
stimulation of the diaphragm in patients with severe heart failure following heart surgery

Conditions: Heart Failure

Summary: this study examines whether a permanent stimulation of the diaphragm improves left ventricular function in patients with severe heart failure following heart surgery.

previous studies have shown that temporary stimulation of the diaphragm using an electrode to the phrenic nerve reduces electrical mechanical activation time (emat) and improves left ventricular function. this study examines whether patients with severe heart failure, who require permanent biventricular pacing after heart surgery, may benefit from an additional permanent electrode that stimulates the diaphragm. heart function is assessed by echocardiography and acoustic cardiography (audicor, inovise medical inc., portland, usa).

Eligibility criteria:
inclusion criteria: * patients following open heart surgery who need permanent pacing exclusion criteria: * patients with fast changing need of vasopressors

Keywords: biventricular pacing
the effect of intraoperative forced air warmer use, on postoperative nausea and vomiting

Conditions: Hypothermia; Anesthesia; Nausea and Vomiting, Postoperative

Summary: intraoperative hypothermia is a common problem, our object will be to evaluate the efficacy of forced air warmer (model # eq-5000) for maintaining core body temperature in patients undergoing laparoscopic surgeries and its effect on postoperative nausea, vomiting and shivering.


Eligibility criteria:
inclusion criteria: * patients undergoing laparoscopic surgeries (hernia repair, cholecystectomy, appendectomy, hysterectomy) * asa category i and ii as per american society of anaesthesiologist classification. * bmi\< 35 kg/m2 * duration of surgery \>1 hour and \<3 hours * patients who consent their participation exclusion criteria: * temperature \>37.5oc or \<35oc, * chronic kidney disease * heart failure * asa category 3\&4 (american society of anaesthesiologist classification) * patients will be withdrawn from the group if their laparoscopy is converted to open surgery